Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria
NCT ID: NCT06050928
Last Updated: 2024-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
33 participants
INTERVENTIONAL
2023-08-30
2024-10-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
EP262 150 mg
Once daily
Oral EP262
Once daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oral EP262
Once daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing to discontinue chronic treatment with antihistamines during the study
Exclusion Criteria
* Other active skin diseases that might confound the study evaluations (eg, atopic dermatitis, bullous pemphigoid, prurigo nodularis, dermatitis herpetiformis)
* Regularly experience wheals covering the area of the body where skin testing will be conducted (eg, more than one third of the volar surface of the forearms)
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Escient Pharmaceuticals, Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Advanced Clinical Research Institute
Tampa, Florida, United States
Treasure Valley Medical Research
Boise, Idaho, United States
Allergy & Asthma Specialists, P.S.C.
Owensboro, Kentucky, United States
Johns Hopkins University
Baltimore, Maryland, United States
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio, United States
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania, United States
National Allergy and Asthma Research, LLC.
North Charleston, South Carolina, United States
Innovaderm Research Inc.
Montreal, , Canada
Gordon Sussman Clinical Research Inc.
North York, , Canada
Medizinische Hochschule Hannover
Hanover, Lower Saxony, Germany
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
Dresden, Saxony, Germany
Institut fur Allergieforschung Charite - Universitatsmedizin Berlin
Berlin, , Germany
Centre for Human Drug Research (CHDR)
Leiden, South Holland, Netherlands
Hospital del Mar
Barcelona, , Spain
Hospital Arnau de Vilanova
Valencia, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EP-262-102
Identifier Type: -
Identifier Source: org_study_id